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Rose KL, Watson AJ, Drysdale TA, Cepinskas G, Chan M, Rupar
CA, Fraser DD. Simulated diabetic ketoacidosis therapy in vitro elicits
brain cell swelling via sodium-hydrogen exchange and anion transport.
Am J Physiol Endocrinol Metab 309: E370–E379, 2015. First published
June 16, 2015; doi:10.1152/ajpendo.00107.2015.—A common compli-
cation of type 1 diabetes mellitus is diabetic ketoacidosis (DKA), a
state of severe insulin deficiency. A potentially harmful consequence
of DKA therapy in children is cerebral edema (DKA-CE); however,
the mechanisms of therapy-induced DKA-CE are unknown. Our aims
were to identify the DKA treatment factors and membrane mecha-
nisms that might contribute specifically to brain cell swelling. To this
end, DKA was induced in juvenile mice with the administration of the
pancreatic toxins streptozocin and alloxan. Brain slices were prepared
and exposed to DKA-like conditions in vitro. Cell volume changes
were imaged in response to simulated DKA therapy. Our experiments
showed that cell swelling was elicited with isolated DKA treatment
components, including alkalinization, insulin/alkalinization, and rapid
reductions in osmolality. Methyl-isobutyl-amiloride, a nonselective
inhibitor of sodium-hydrogen exchangers (NHEs), reduced cell swell-
ing in brain slices elicited with simulated DKA therapy (in vitro) and
decreased brain water content in juvenile DKA mice administered
insulin and rehydration therapy (in vivo). Specific pharmacological
inhibition of the NHE1 isoform with cariporide also inhibited cell
swelling, but only in the presence of the anion transport (AT) inhibitor
4,4=-diisothiocyanatostilbene-2,2=-disulphonic acid. DKA did not al-
ter brain NHE1 isoform expression, suggesting that the cell swelling
attributed to the NHE1 was activity dependent. In conclusion, our data
raise the possibility that brain cell swelling can be elicited by DKA
treatment factors and that it is mediated by NHEs and/or coactivation
of NHE1 and AT.
children; diabetic ketoacidosis; treatment; cell swelling; sodium-hy-
drogen exchangers; anion transport
TYPE 1 DIABETES MELLITUS IS OFTEN COMPLICATED by diabetic
ketoacidosis (DKA), a state of hyperglycemia with accumula-
tion of acidic ketone bodies in blood (54). Early recognition
and treatment of DKA is critical to avoid hyperosmolar coma
and death. DKA is treated with insulin and rehydration in a
monitored hospital setting; however, a potential consequence
of DKA and its therapy in children is cerebral edema (DKA-
CE). DKA-CE mortality is estimated at 21–25%, with signif-
icant neurological morbidity at 15–26% (37). Both vasogenic
and cellular mechanisms are implicated in DKA-CE (29, 34,
49); however, the pathological mechanisms of therapy-induced
DKA-CE are largely unknown (37).
Clinical studies link young age, longer duration of symp-
toms, and increased DKA severity to the development of
DKA-CE (9, 37). Treatment factors implicated in the develop-
ment of DKA-CE include bolused administration of either
insulin or bicarbonate (20, 21, 27), suggesting that rapid
correction of glucose and acidosis in DKA may aggravate
DKA-CE via osmolar shifts and/or alkalinization.
A role for the sodium hydrogen exchanger (NHE) in
DKA-CE had been proposed previously but not investigated
(51). NHE1-9 are a family of transporters that regulate pH and
cell volume by exchange of one intracellular H for an extra-
cellular Na (15, 40). In the brain, the NHE1 isoform is widely
distributed and expressed in both neurons and astrocytes (38,
46). In contrast, NHE2-5 expression is region specific and
significantly lower than NHE1 (6, 7, 11, 15, 38). NHE1 activity
is essential for regulation of intracellular pH, and NHE1 is
stimulated by insulin, acid loads, and hypo-osmotic stress (46,
50). Parallel activity of NHE1 and anion transport (AT) im-
proves the efficiency of intracellular pH and cell volume
regulation (2, 12, 30, 35).
In this study, we hypothesized that activation of membrane
transporters with DKA therapies would induce brain cell swell-
ing. Our aims were to investigate the DKA treatment factors
that might contribute to cell swelling in a brain slice model and
to investigate whether NHE and/or AT membrane transporters
contribute to cell volume changes.
METHODS
This study was approved by the University Council on Animal
Care at Western University (London, ON, Canada).
Mouse model of DKA. We used our juvenile mouse model of DKA
that develops DKA-CE with rehydration and insulin therapy (49).
Briefly, 21-day-old mice were administered 200 mg/kg ip of both
streptozocin (STZ) and alloxan (ALX). STZ-ALX was dissolved by
cold citrate buffer (10 mM, pH 4.5) in glass immediately before
injection. Control mice received the same volume of citrate buffer
only. Tail vein blood analysis showed that mice developed DKA 72 h
after STZ-ALX injection. DKA-CE was induced by ip injection with
3 ml of rehydration solution containing bicarbonate and insulin (1 U
R and 1 U NPH; Eli Lilly, Toronto, ON, Canada). Brain water content
(BWC) was measured as an indicator of DKA-CE and reflects the
wet-to-dry brain weight ratio (49).
Brain slices. Brain slices were obtained from juvenile control and
DKA mice (28–35 days old), as described previously (19, 20).
Briefly, mice were sedated with midazolam (20 mg/kg ip) and
immediately decapitated. Coronal brain slices were cut in ice-cold
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DKA artificial cerebrospinal fluid (DKA aCSF; Table 1) containing
0.5 mM kynurenic acid on a Vibratome Series 1000 (Warner Instu-
ments, Hollister, MA). Slices were incubated in DKA aCSF at room
temperature for 2 h before experiments were performed. Solution pH
and oxygen levels were maintained by intermittent bubbling with 5%
CO2 (pH controller; Harvard Instruments) and with continuous bub-
bling with 100% O2, respectively. For imaging, brain slices were
individually submerged in a tissue bath on an inverted microscope
(Zeiss, Toronto, ON, Canada) and rapidly perfused (4 ml/min) with
DKA aCSF.
Experimental aCSF composition. For DKA imaging experiments,
brain slices were perfused with DKA aCSF for 5 min before being
switched over to an experimental aCSF for 25 min (Table 1). CSF
composition in children with DKA is generally unknown, as a lumbar
puncture might instigate transtentorial brain herniation secondary to
elevated intracerebral pressure. One study on a mixed population of
adults and adolescents demonstrated that DKA CSF had increased
glucose, ketones, lactate, and osmolality, whereas the bicarbonate was
reduced (44); during DKA treatment, all values approached normal
values. Noninvasive NMR and MRS imaging have also demonstrated
altered CSF composition during DKA, which included elevated glu-
cose, lactate, and ketones, and reduced intracerebral pH (8, 13, 28,
55). Thus, experimental aCSF was approximated to these studies. The
name of each aCSF indicates the components that change from DKA
aCSF. For example, in Alk/Ins aCSF, aCSF pH was alkalinized using
increased bicarbonate, and reduced lactate and -OH-butyrate and
insulin were added. NaCl concentrations were adjusted to maintain
targeted osmolalities, a common method for maintaining osmolality in
neurophysiology studies (42). Osmolalities were measured in tripli-
cate on a calibrated osmometer prior to each experiment and varied by
5 mOsmol. For control experiments, brain slices were perfused with
only DKA aCSF throughout the experiments (Fig. 1).
Imaging light transmittance. Increased light transmittance (LT)
imaged in brain slices provides an accurate measurement of cellular
swelling; the technique has been described in detail previously (31,
39). Prior to all brain slice imaging experiments, low baseline LT was
confirmed and verified tissue viability (5). Briefly, images of the
hippocampus from 500 M brain slices were acquired every 10 s with
a digital charge-coupled device (CCD) camera controlled by Northern
Eclipse Imaging Software (Empix Imaging, Mississauga, ON, Can-
ada). The first image served as control (Tcont), and subsequent exper-
imental images were subtracted in a pixel-by-pixel fashion from the
control image (Texp  Tcont). This value was divided by the Tcont and
the gain of intrinsic signal and then expressed as a percentage of the
digital intensity of the control image: LT  (Texp  Tcont)/(gain 
Tcont)  100  	T/T%. The control image was displayed in bright
field, and each subtracted image was displayed, with the change in LT
for each pixel indicated using pseudocolour intensity scale. Regions of
interest (ROI) were identified in the control image, and size and
positioning were consistent in all experiments (CA1 stratum radia-
tum). LT time points were averaged over several experiments and then
graphed over time. For graphical comparison, mean LT for each
experimental time point was subtracted from the mean LT for its
respective time point on the baseline recording. For statistical analy-
sis, experimental LT was averaged at a single time point (22 min)
without subtraction (raw data).
Imaging calcein fluorescence. Neurons load preferentially with
calcein-am in brain slices (31). Briefly, 150- to 300-m brain slices
were incubated for 1 h in DKA aCSF containing calcein (20 M;
Invitrogen, Carlsbad, CA) and then rinsed for 20 min in DKA aCSF.
Brain slices were individually transferred to an imaging chamber and
perfused with DKA aCSF, and the hippocampus was viewed with an
inverted microscope. Calcein was excited with light from a xenon
lamp passed through a 485-nm excitation filter cube every 10 s
controlled by Northern Eclipse Software. After passing through a
440-nm emission filter, images were acquired every 10 s by a CCD
camera. ROI were identified in the control image, and size and
positioning were consistent in all experiments (CA1 stratum radia-
tum). To control for possible variation in calcein loading and auto-
fluorescence between slices, mean fluorescence of the ROI from the
initial image was subtracted from all subsequent images to calculate
the net change in fluorescence at each time point. Time points were
averaged from several brain slices and then graphed against time. For
statistical analysis, change in fluorescence was averaged at a single
time point (20 min).
Brain taurine measurements. Brains from DKA and control juve-
nile mice were isolated, weighed, and homogenized by sonication in
1 ml of a solution containing 5-sulfosalicylic acid (0.2M) and S-(2-
aminoethyl)-L-cysteine (0.17 mM) in a lithium citrate (133 mM)
buffer, pH 2.6. A dilution of the brain homogenate was analyzed on
a Biochrom 30 amino acid analyzer (Biochrom, Cambridge, UK) that
measures the concentration of physiological amino acids, including
taurine with postcolumn ninydrin derivatization and using S-(2-ami-
noethyl)-L-cysteine as an internal standard. Data are expressed as
nanomoles per milligram dry weight.
Physiological salts, reagents, and drugs. All reagents were pur-
chased from Sigma-Aldrich (Oakville, ON, Canada) unless otherwise
specified. Methyl-isobutyl-amiloride (MIA; LT, 50 M; in vivo, 50
mg/kg) was solubilized in dimethylsulfoxide (DMSO) and then di-
luted 1:1,000 into DKA aCSF. Cariporide (1 M; gift of Drs. H.
Kleeman, W. Linz, and J. Pünter; Sanofi Aventis, Frankfurt, Ger-
many) was serially diluted in distilled water and then into DKA aCSF.
KR-33028 (30 M; gift of Dr. K. H. Kim; Yonsei University College
of Medicine, Seoul, South Korea) was solubilized in DMSO and then
diluted 1:1,000 into DKA aCSF. DIDS (4,4=-diisothiocyanatostilbene-
2,2=-disulphonic acid; 500 M) was added directly to DKA aCSF. For
LT imaging experiments, antagonists were added to DKA aCSF and
experimental DKA aCSF solutions throughout the experiment.
NHE1 genotyping. Genotyping was performed using polymerase
chain reaction (PCR), as described previously (22). Primers were
synthesized by Sigma-Aldrich (wild type forward: 5=-CCT GAC CTG
GTT CAT CAA CA-3=; mutant forward: 5=-CCT GAC CTG GTT
CAT CAA CT-3=; common reverse: 5=-TCA TGC CCT GCA CAA
AGA CG-3=). PCR products were run on a 1.5% agarose gel contain-
ing ethidium bromide.
NHE1 immunoblotting. Flash-frozen dissected mouse brain regions
isolated 72 h after STZ-ALX or sham injection were homogenized in
ice-cold RIPA buffer containing a broad-range protease inhibitor
Table 1. Components of DKA aCSF and simulated DKA therapy aCSFs
pH Bicarbonate, mM Sodium, mM Glucose, mM Osmol, m -OH-butyrate, mM Lactate, mM Insulin, M
DKA aCSF 7.1 10 134 30 344 4 4 0
Alk 7.4 26 122 30 344 0 0 0
Ins 7.1 10 134 30 344 4 4 0.1
Alk/Ins 7.4 26 122 30 344 0 0 0.1
2Osmol 7.1 10 117 10 290 4 4 0
DKA corrected 7.4 26 105.5 10 291 0 0 0.1
DKA, diabetic ketoacidosis; aCSF, artificial cerebrospinal fluid; Alk, alkalinization; Ins, insulin; Osmol, osmolality. DKA-corrected aCSF included Alk/Ins
and decreased Osmol. Components that were common to all aCSFs are as follows (in mM): 3.3 KCl, 1.1 MgSO4, 2.0 CaCl2, and 1.1 NaH2PO4.
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cocktail (Calbiochem, La Jolla, CA) and then centrifuged at 1,000 g
for 20 min to remove insoluble material. NHE1 expression was
detected as described previously, with some modifications (47).
Briefly, 20 g of protein from each sample was mixed with Laemmli
loading buffer and run on a 10% sodium dodecyl sulfate polyacryl-
amide gel electrophoresis gel. The samples were transferred onto
PVDF membrane at 30 V overnight at 4°C. The membrane was
blocked with 5% nonfat milk in TBS-T for 1 h and then incubated
overnight at 4°C with NHE1 antibody (1:1,000; Chemicon, Temicula,
CA). The membrane was blocked with 5% nonfat milk in TBS-T with
frequent changes and then incubated for 1 h with anti-mouse antibody
conjugated to horseradish peroxidase (Cell Signaling Technology,
Danvers, MA). Antibody binding was detected with chemilumines-
cent reagent (Lumiglo Reagent; Cell Signaling Technology).
Statistics. Data are presented as means 
 SE. Data groups were
prescreened for normality and then compared with either a Student’s
t-test or Mann-Whitney U-test. Multiple groups were compared with
analysis of variance and Holm-Sidak post hoc test. A P value of
0.05 was considered significant.
RESULTS
For LT imaging experiments, data traces were collected
from brain slices that underwent simulated DKA therapy (cor-
rected DKA) and from brain slices that remained in DKA-like
conditions as controls (DKA-only) (Fig. 1A). Time points from
multiple experiments were averaged to create the raw DKA-
corrected trace and the raw DKA trace, respectively (Fig. 1B).
The raw DKA trace was subtracted from the DKA-corrected
trace to obtain the subtracted DKA-corrected data, which
represents the net effect of simulated DKA therapy on cellular
DKA-CE (Fig. 1C).
The first aim of this study was to determine which compo-
nents of DKA therapy could potentially lead to cellular DKA-
CE, including aggressive insulin administration, or rapid cor-
rection of either acidosis or hyperosmolality (Table 1). Simu-
lated DKA therapy resulted in a significant increase in LT or
cell edema at 22 min in brain tissue treated with either
alkalinization alone (38.1% increase in LT) or with combined
insulin and alkalinization (70% increase in LT) (Fig. 2, A and
B). The greatest increase in LT resulted from complete DKA
correction with insulin, alkalinization, and decreased osmola-
lity (99.4% increase in LT) as well as decreased osmolality
alone (98.9% increase in LT). No significant difference in LT
was observed with therapy consisting of insulin only (6.4%
increase in LT), consistent with the low bioavailability of
insulin in acidic media (24). Overall, these data suggest that
multiple DKA treatment factors potentially cause cellular
DKA-CE.
Previous research has suggested that osmotic disequilibrium
in brain cells during DKA therapy is due in part to intracellular
idiogenic osmoles that are elevated to compensate for the
DKA-associated hyperosmolality (33). Given the cell swelling
Fig. 1. Imaging light transmittance (LT; cell edema) in hippocampal slices during simulated diabetic ketoacidosis (DKA) therapy. A: representative LT Images.
Shown are 1) an initial grayscale image of the brain slice with the standard region of interest (box) in the CA1 stratum radiatum, 2) a pseudocolor LT image
from a brain slice perfused in DKA artificial cerebrospinal fluid (DKA aCSF) for 20 min, and 3) a pseudocolor LT image from a brain slice during DKA
correction aCSF for 15 min. The pseudocolor scale represents progressive cell swelling and progresses as follows: blue  green  yellow  red. B: raw traces.
LT data were collected from a single region of interest over the course of an experiment. For this figure, each averaged trace is from 3 independent experiments.
The switchover to DKA-corrected solution is indicated by a single arrow, and the time at which images (A2, A3) were obtained is indicated by double arrows.
To control for non-experimental sources of cell swelling, raw averaged traces of LT were obtained from a separate brain slice in DKA-aCSF only (no switchover).
C: baseline subtraction. LT from the DKA trace (red line in B) was subtracted from the experimental trace (blue line in B) to obtain the averaged subtracted
DKA-corrected trace (purple line), which represents the net effect of simulated DKA correction. DG, dentate gyrus.
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due to decreased osmolality measured above, we tested for
evidence of increased intracellular taurine, a primary idiogenic
osmole, in DKA brain tissue. Our data confirmed that juvenile
DKA mice had significantly elevated brain taurine compared
with control mice (brain taurine concentrations were 3.0 
 0.1
and 2.5 
 0.2 nmol/mg dry wt in DKA and control brains,
respectively; P  0.05, n  9–10/group; Fig. 2C), potentially
adding to the osmotic gradient across the brain cell membrane
during DKA correction.
The role of NHEs in cellular DKA-CE was assessed with
MIA, an NHE inhibitor. MIA reduced cellular DKA-CE
significantly in brain tissue treated with DKA-corrected
aCSF (67% decrease in LT; Fig. 3, A and C). MIA failed to
reduce cell swelling in brain tissue treated with Alk/Ins
aCSF (29% decrease in LT; Fig. 3, B and C), indicating that
MIA-sensitive NHEs likely mediate the osmotic component
of cellular DKA-CE.
Since MIA crosses the blood-brain barrier (BBB) (22), in
vitro data was confirmed in vivo using juvenile DKA mice that
develop DKA-CE when treated with insulin and rehydration
fluid (49). Mice injected with STZ-ALX developed DKA, as
indicated by elevated blood glucose (DKA 29.3 
 0.4 mmol/l,
n  66; control 10.5 
 0.3 mmol/l, n  35; P  0.001) and
-OH-butyrate (DKA 4.46 
 0.08 mmol/l, n  66; control
0.19 
 0.02 mmol/l, n  35; P  0.001), as well as decreased
body weight (DKA 18.7
 0.2 mmol/l, n 66; control 23.9

0.4 mmol/l, n 35; P 0.001). DKA therapy resulted in rapid
correction of serum glucose (7.6 
 0.8 mmol/l, n  34, P 
0.001) and was associated with increased brain water content,
consistent with the development of DKA-CE. Administration
of MIA to DKA mice significantly reduced the DKA-CE
elicited with DKA therapy (Fig. 3D), indicating that activity of
brain NHEs contribute to cellular DKA-CE.
To better define the cellular origin of cellular DKA-CE,
we imaged calcein fluorescence dye dilution in brain slices
as an indicator of the neuronal swelling (31) during simu-
lated DKA therapy. Calcein dye dilution experiments sug-
gest that simulated DKA therapy elicits cell swelling in the
stratum radiatum that is at least in part neuronal in origin
(81% decrease in fluorescence; n  3; Fig. 4A). Neuronal
swelling with simulated DKA therapy is supported by the
observation that calcein dilution was similar in the stratum
pyramidale, an anatomic region with neuronal cell bodies
that is largely devoid of glia (n  3; data not shown). MIA
pretreatment of calcein-loaded brain slices failed to signif-
icantly reduce cell swelling elicited with simulated DKA
therapy (10% decrease in fluorescence, n  5; Fig. 4B),
indicating that the MIA-sensitive osmotic component re-
sides in nonneuronal cells such as astrocytes.
Chronic acidosis increases NHE1 expression in some tissues
(25); however, NHE1 expression determined using immuno-
blotting was similar in both control and DKA cortex [optical
density (OD)C  2.4 
 0.4 arbitrary units (AU); ODDKA 
2.4 
 0.5 AU], hippocampus (ODC  2.3 
 0.5 AU;
ODDKA  2.4 
 0.5 AU), brainstem-diencephalon (ODC 
2.2 
 0.5 AU; ODDKA  2.2 
 0.5 AU), and cerebellum
(ODC  2.5 
 0.4 AU; ODDKA  2.7 
 0.4 AU) (P  0.948,
n  4/group; Fig. 5, A and 5B). Similar NHE1 expression
levels were also observed in both control and DKA brain
following fractioning and immunoblotting of membrane vs.
cytosolic components (data not shown; n  3/group). Finally,
similar levels of cellular DKA-CE were elicited in brain slices
obtained from either control (sham-injected) or DKA (STZ/
ALX-injected) mice (134.8 and 78.4% increase in LT, respec-
tively; Fig. 5C) preincubated for 2 h in DKA aCSF. Taken
together, these results demonstrate that NHE1 expression is
unchanged by DKA.
Fig. 2. Simulated DKA therapies (Table 1) cause cell swelling in hippocampal
slices. A: simulated DKA therapies elevate LT (cell edema) after baseline
subtraction. B: statistical analysis confirms that DKA corrected aCSF, de-
creased osmolality aCSF, insulin/alkalinization (Ins/Alk) aCSF, and Alk alone
aCSF lead to significant cell swelling. Statistical analysis was performed at 22
min with raw (nonsubtracted) LT values (*P  0.05, n  5–29). C: a bar
diagram illustrating the increased taurine in brains of DKA juvenile mice
compared with control juvenile mice (*P  0.05, n  9–10 animals/group).
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Slow-wave epilepsy (“swe”) mice, which endogenously ex-
press a mutated NHE1 (17), were used to determine whether
NHE1 activity is important for cellular DKA-CE during DKA
therapy. Genotyping and Western blotting confirmed that
NHE1 expression was significantly reduced in swe/ mouse
brain, and NHE1 was altogether absent in swe/swe mice (n 
3/group, 1 forebrain/sample, OD/  5.94 
 0.38 AU,
ODswe/  2.98 
 0.62 AU, ODswe/swe  0.05 
 0.04 AU,
P  0.05; Fig. 6, A and B). Swe/swe mice did not survive to
juvenile age (35 days postnatal) for DKA induction in vivo,
and brain slices from swe/swe mice did not survive incubation
in DKA aCSF (n  5; LT values were exceedingly high, and
tissue failed to respond to osmotic stimuli). These data suggest
that NHE1 expression is critical for brain tolerance and cell
survival during DKA. In contrast, swe/ mice survived DKA
conditions despite a 50% reduction in NHE1 expression. Im-
aging LT showed that DKA correction caused cellular
DKA-CE in live brain slices from swe/ mice (91.8% increase
in LT) that was similar to cellular DKA-CE in brain slices from
wild-type littermates (116.1% increase in LT; Fig. 6, C and D).
Moreover, like NHE1/ mice, we observed DKA-CE in vivo
when DKA swe/ were treated therapeutically with insulin
and rehydration fluid (swe/ DKA, BWC  3.55 
 0.2 l/kg
dry brain wt; swe/ DKA-CE, BWC  3.71 
 0.03 l/kg dry
brain wt; Fig. 6E).
Since the 50% reduction in NHE1 expression in swe/ mice
may not be sufficient to inhibit cellular DKA-CE, we also used
two potent NHE1 isoform-specific antagonists to inhibit cellu-
lar DKA-CE [KR-33028 (32) and cariporide (41)]. Cellular
DKA-CE was not reduced by pharmacological inhibition of
NHE1 with either cariporide (3.15% increase in LT; Fig. 7A) or
KR-33028 (1.4% increase in LT; Fig. 7B). An inhibitor of AT
also failed to reduce cellular DKA-CE (DIDS, 13.4% increase
in LT; Fig. 7C). In contrast, coinhibition of NHE1 and AT with
application of cariporide and DIDS, respectively, partially
reduced cellular DKA-CE (15.1% decrease in LT; Fig. 7D).
Thus, both NHE1 and AT have compensatory actions and
require coinhibition to reduce cellular DKA-CE elicited by
DKA therapy.
DISCUSSION
In this study, we used an in vitro paradigm (33) to investi-
gate the potential DKA therapies and membrane mechanisms
contributing to cellular DKA-CE. DKA-CE occurs almost
exclusively in children, typically within the first 24 h of DKA
therapy (20, 29). Clinical studies suggest that bolused insulin,
bicarbonate administration, and/or rapid rehydration may pre-
cipitate DKA-CE (20, 21, 27). Previously, we reported that
DKA-CE was elicited with combined insulin/bicarbonate ad-
ministration in juvenile DKA mice (49) and now extend our
investigations to live brain slices. The DKA correction with
simulated DKA therapy in vitro mimics an insulin bolus in
combination with rapid alkalinization and reduction in osmo-
Fig. 3. Nonselective sodium hydrogen ex-
changer (NHE) antagonism with methyl-
isobutyl-amiloride (MIA) reduces both cel-
lular DKA-CE in vitro and DKA-CE in vivo.
A–C: in vitro NHE antagonism. Nonselec-
tive NHE antagonism with MIA inhibits the
osmotic component of cellular DKA-CE in-
duced by DKA-corrected aCSF, as MIA
failed to inhibit the cellular swelling elicited
by Alk/Ins aCSF (*P  0.05, n  10–20).
D: in vivo NHE antagonism. Pretreatment
with MIA (50 M) significantly reduced
brain water content (DKA-CE) in DKA-
treated mice compared with those pretreated
with vehicle only (*P  0.05, n  26–28).
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lality. Mechanistic studies on the origins of cellular DKA-CE
were accomplished by altering aCSF composition during sim-
ulated DKA therapy.
To our knowledge, this is one of the few studies to use in
vitro techniques to directly study DKA-CE (33) and the first to
use intact brain slices that allow for preservation of both intact
neuron-astrocyte relationships and synaptic functions and per-
mits accurate drug dosing for transporter inhibition. Brain slice
experiments also allow for the exclusive study of cell edema
independent of changes in cerebral blood flow and vasogenic
edema (1, 5). Finally, cell edema is accurately quantified in
brain slices by imaging either LT or intracellular calcein dye
dilution (3, 31, 39).
The CSF composition is altered by DKA (44), possibly
because of increased BBB permeability. BBB dysfunction may
be secondary to DKA-associated inflammation and leukocyte
adherence to the brain microvascular endothelium (16, 45).
DKA-induced BBB permeability may exacerbate increases in
brain glucose, lactate, and ketone levels during DKA (13, 28,
55) and underlie the vasogenic edema observed on brain MRI
with apparent diffusion coefficients (19, 23, 29). In this study,
we examined the potential for cellular DKA-CE to be mediated
by changes in CSF composition during DKA therapy. Our data
suggest that rapid alkalinization (with or without insulin)
and/or a rapid decrease in osmolality in CSF could lead to
cellular DKA-CE in children during DKA therapy. These data
are in agreement with previous in vivo data (49), where many
factors exist that are not present under in vitro conditions (i.e.,
circulating counterregulatory hormones, inflammatory factors,
etc.). Our data may also explain why clinical studies have had
Fig. 4. Neuronal swelling elicited by simulated DKA therapy as determined by
calcein fluorescence dilution imaging. A: averaged normalized fluorescence (F)
traces show that neuronal swelling occurs in brain slices treated with DKA-
corrected aCSF. Black arrow indicates time of switchover from DKA aCSF to
DKA-corrected aCSF. Inset: statistical analysis at 20 min shows that the F
signal decreased in brain slices treated with DKA-corrected aCSF (pink)
compared with DKA aCSF (blue) (*P 0.001, n 3). B: calcein-loaded brain
slices were pretreated with MIA and treated with DKA-corrected aCSF.
Statistical analysis at 20 min shows that NHE antagonism does not inhibit
neuronal swelling (*P  0.05, n  5).
Fig. 5. DKA does not change brain NHE1 expression. A: representative
immunoblot showing that NHE1 expression is not elevated in DKA cortex
(CO), hippocampus (HC), brainstem-diencephalon (BD), or cerebellum (CB).
B: optical densitometry (OD) confirms that NHE1 expression does not differ
between control and DKA mouse brain (n  3); each sample contained tissue
from 3 (CO), 4 (CB, BD), or 5 (HC) mice. C: statistical analysis reveals no
significant differences in cellular edema between control (C; sham-injected)
and DKA (streptozotocin/alloxan-injected) mouse brain (D) slices when
treated with DKA-corrected aCSF (*P  0.05, n  4–10).
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difficulty identifying a single therapeutic component that
causes DKA-CE.
NHEs are hypothesized to underlie cell swelling in
DKA-CE (51). In this study, DKA mice that were pretreated
with MIA exhibited significantly decreased BWC after DKA
therapy, supporting the hypothesis that NHE activity might
in part underlie DKA-CE. To determine whether the inhib-
itory action of MIA on DKA-CE was due to reduced cellular
DKA-CE, as opposed to vasogenic accumulation of extra-
cellular fluid, we performed in vitro experiments specifically
examining cellular edema. Indeed, a reduction in cellular
DKA-CE after pretreatment with MIA was observed in brain
slices following simulated DKA therapy. MIA failed to
inhibit cell swelling due to simulated therapy with only
bicarbonate-insulin in the absence of an osmolar decrease.
Taken together, our data suggest that the NHE antagonist
MIA inhibits only the osmotic-mediated component of cell
swelling during simulated DKA therapy.
Fig. 6. Analysis of DKA-cerebal edema
(DKA-CE) in NHE1 mutant [slow-wave ep-
ilepsy (swe)] and wild-type mice. A: geno-
types of swe mouse line pups were deter-
mined by PCR analysis. B: representative
immunoblot showing reduced functional
NHE1 expression in swe/ mice (P  0.05,
n  3). C and D: in vitro experiments.
Imaging reveals significant LT increases at
22 min in brain slices from swe/ and /
mice during treatment with DKA-corrected
aCSF (ANOVA with Holm-Sidak post hoc
test; *P  0.05, n  5–9). E: in vivo exper-
iments. Elevated BWC (DKA-CE) was ob-
served 2 h after DKA therapy in swe/ mice
despite a 50% reduction in NHE1 expression
(*P  0.001, n  11–16).
Fig. 7. Coinhibition of NHE1 and anion transport inhibit
cellular DKA-CE. Statistical analysis shows no differ-
ences in nonsubtracted LT values at 22 min in brain
slices pretreated with the specific NHE1 inhibitors ca-
riporide (P  0.732, n  5; A) or KR-33028 (P 
0.880; n  4–6; B). Pharmacological inhibition of
anion transport with DIDS (4,4=-diisothiocyanatostil-
bene-2,2=-disulphonic acid) also failed to reduce cellu-
lar DKA-CE (P  0.249, n  5; C). In contrast,
coinhibition of both NHE1 and anion transport de-
creased significantly LT at 22 min (P  0.034, n  6).
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Both neurons and astrocytes are important sources of LT in
brain slice experiments (3). For this study, LT was imaged
from within the CA1 stratum radiatum, an easily identifiable
region enriched with neuronal apical dendrites and with a
relatively small number of astrocytes (52). Neuronal swelling
in response to simulated DKA therapy was further suggested
by calcein fluorescence dilution imaging (31). Concurrent
neuronal and astrocytic swelling has been observed previously
in a model of ischemic brain injury (48), but only astrocytic
swelling is observed in brain slices exposed to hypo-osmotic
stimuli (4, 48). Thus, our data suggests that the neuronal
swelling due to simulated DKA therapy is not mediated by a
hypo-osmotic shift but perhaps by rapid alkalinization and/or
the addition of insulin.
Pretreatment with MIA had no effect on neuronal swelling,
as observed in calcein dye dilution experiments, suggesting
that MIA inhibited only NHEs on astrocytes that are exqui-
sitely sensitive to osmotic swelling. Indeed, astrocytes rapidly
alter cell volume in response to osmotic stress via aquaporin
channels, whereas neuronal swelling occurs slowly, due to
other uncharacterized transport mechanisms (4, 48). Based on
our MIA data, we conclude that neuronal and astrocytic swell-
ing are mediated by different mechanisms during DKA ther-
apy. Ultimately, precise determination of the relative contribu-
tions of neuronal and astrocytic swelling to DKA-CE will
require two photon microscopy combined with cell-specific
expression of fluorescent indicators (18, 43).
NHE1 is a key regulator of cell volume and pH in brain (46),
and NHE1 expression is upregulated in several tissues by
chronic acidosis (25) and/or hyperglycemia (53). Surprisingly,
NHE1 expression was not elevated in DKA brain tissue, which
is when aggressive DKA therapy may instigate cellular DKA-
CE. In addition, cellular DKA-CE with simulated DKA ther-
apy was similar in brain slices obtained from control and DKA
mice. Together, these data indicate that NHE activity, but not
expression, is increased by DKA therapy.
To define the role of NHE1 activity in DKA-CE, NHE1
mutant mice were employed in both brain slice (in vitro) and
BWC (in vivo) experiments. The NHE1 mutant mice did not
survive for the induction of DKA, and brain tissue from NHE1
mutant mice did not survive incubation in DKA aCSF. Thus,
NHE1 is critical for brain tolerance and cell survival during
DKA. Swe/ mice, which express about half the functional
NHE1 of wild-type mice, exhibited elevated BWC after DKA
therapy, and in vitro experiments showed cell swelling in
swe/ mouse brain slices during simulated DKA therapy.
These data indicate that partial expression of NHE1 is suffi-
cient for cell swelling in DKA-CE, although it is also possible
that other NHE isoforms or transporters functionally compen-
sated for NHE1 in swe/ mice (56).
To further define the role of NHE1 activity in cell swelling
during DKA therapy, two highly selective NHE1 inhibitors,
KR-33028 (32) and cariporide (41), were employed. NHE1
antagonists failed to inhibit the development of cellular
DKA-CE during simulated DKA therapy, indicating that
NHE1 inhibition alone cannot reduce cell swelling with DKA
therapy. The brain tissue in these NHE1 antagonist experi-
ments survived, and cell edema occurred in response to simu-
lated DKA therapy, yet NHE1 mutant mouse brain tissue did
not survive similar circumstances. The lack of tissue death
observed during pharmacological inhibition of NHE1 suggests
that NHE1 inhibition may be incomplete, or it may indicate
that brain cells are capable of surviving in DKA conditions
during transient but not permanent NHE1 inhibition.
MIA crosses the BBB and is a potent and specific NHE
antagonist at the concentration used in this study (22, 26). MIA
reduced DKA-CE in vivo and cellular DKA-CE in vitro during
simulated DKA therapy, yet specific NHE1 antagonism did not
reduce cell edema during simulated DKA therapy, suggesting
an alternate mechanism for MIA. MIA may reduce cell swell-
ing through the inhibition of NHE2-5 or perhaps by interacting
with a currently unknown membrane transporter.
Neurons and astrocytes regulate intracellular pH using a
number of ion transporters (15), and thus regulation of intra-
cellular pH may occur even if one type of transporter is
inhibited (36). Our results show that combined inhibition of
NHE1 and AT are required to reduce cell swelling elicited in
brain tissue with simulated DKA therapy. Studies show that
both neuronal pH regulation (10) and regulatory volume in-
creases in many cell types rely on tandem activation of NHE
and AT (2, 30, 35). In vivo antagonism of Na-K-2Cl cotrans-
port (NKCC) resulted in reduced cortical edema in DKA-CE
mice, which suggests that NKCC may also contribute
DKA-CE (34). Taken together, these studies suggest that
inhibition of multiple NHE isoforms and/or multiple types of
transporters should be more effective at reducing cellular
DKA-CE than inhibition of a single isoform of NHE.
There are limitations to this study. First, although brain
slices offer excellent experimental control, physical damage to
the superficial surface may occur during preparation, and
ischemia may occur at the tissue core. To reduce brain slice
variability and potential tissue hypoxia, all brain slices were
examined for viability before experiments, and oxygenated
aCSF flow rates were maximized to reduce tissue hypoxia.
Second, although we have attempted to mimic changes in the
CSF composition during DKA therapy, CSF from children
with DKA is not well defined. Thus, we investigated putative
changes in CSF composition that are thought to occur in
children with DKA as a result of increased BBB permeability
(13, 19, 23, 29). It is also well established that systemic insulin
crosses the BBB (8); however, studies have not yet addressed
whether insulin resistance occurs in brain cells during DKA.
Third, our work focuses on mechanisms of cell edema in
hippocampal tissue during DKA, and we concede that cell
swelling mechanisms may vary in other brain regions. Fourth,
since this work was done with a mouse DKA model admin-
istered pancreatic toxins, caution must be used when extrap-
olating to human DKA. Unfortunately, we are not aware of
other suitable juvenile DKA mouse models, and although
the nonobese diabetic (NOD) mouse is similar in many
respects to human autoimmune diabetes, NOD mice do not
fully develop diabetes until adulthood, and they are resistant
to ketoacidosis (14). Despite these study limitations, our
data demonstrate the potential for aggressive DKA therapy
to cause cellular DKA-CE.
In summary, we demonstrate that multiple DKA treatment
factors can potentially elicit cell edema, including alkaliniza-
tion, insulin/alkalinization, and reduced osmolality (exacer-
bated by increased brain taurine), and that both neurons and
astrocytes may swell in response to simulated DKA therapy.
These results support clinical recommendations for slow and
cautious treatment of children with DKA to reduce the chances
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of instigating cellular DKA-CE by causing rapid and/or drastic
changes in CSF pH, insulin levels, and/or osmolality during
DKA therapy. Interestingly, general inhibition of NHE with
MIA may reduce osmotic cell edema in astrocytes but not
neurons. Moreover, our data provides the first experimental
evidence that NHE activity and/or combined NHE1/AT might
contribute to cellular DKA-CE.
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